Company: AGIO
Filing Date: 2025-07-31
Form Type: 10-Q
Source: 0001439222-25-000089
Chunk: 154

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-07-31
Form: 10-Q
Item: Part I, Item 1
Chunk 154
---
 with the phase 3 ENERGIZE and ENERGIZE-T trials, partially offset by increased professional expenses.  The increase in our indirect expenses was primarily due to an increase in compensation and related expenses, driven principally by workforce-related expenses.

Other Income and ExpenseThree Months Ended June 30,Six Months Ended June 30,(In thousands)2025202420252024Interest income, net$14,513 $8,120 $30,600 $17,009 Other income, net523 1,579 1,776 3,213 

Other Income and Expense - Three Months Ended June 30, 2025 vs. Three Months Ended June 30, 2024 –  The increase in interest income, net in the three months ended June 30, 2025 compared to the three months ended June 30, 2024 was primarily attributable to increased return on our investments and an increased investment balance.

Other Income and Expense - Six Months Ended June 30, 2025 vs. Six Months Ended June 30, 2024 –  The increase in interest income, net in the six months ended June 30, 2025 compared to the six months ended June 30, 2024 was primarily attributable to increased return on our investments and an increased investment balance. 

Net LossThree Months Ended June 30,Six Months Ended June 30,(In thousands)2025202420252024Net loss$(112,020)$(96,118)$(201,309)$(177,667)

Net Loss - Three Months Ended June 30, 2025 vs. Three Months Ended June 30, 2024 – The increase in net loss for the three months ended June 30, 2025 compared to the three months ended June 30, 2024 was primarily driven by the increase in research and development expenses discussed above in Research and Development Expenses, and the increase in selling, general and administrative expenses discussed above in Total Operating Expenses, partially offset by the increase in interest income, net discussed above in Other Income and Expense, and the increase in product revenue discussed above in Revenue.

Net Loss - Six Months Ended June 30, 2025 vs. Six Months Ended June 30, 2024 – The increase in net loss for the six months ended June 30, 2025 compared to the six months ended June 30, 2024 was primarily driven by the increase in selling, general and